Propafenone
پروپافنون
❤️ Cardiovascular SystemClass IC antiarrhythmic
Market / country: 🇺🇸 USA
Rythmol (US)
🧮 Dose calculator
Atrial fibrillation / anticoagulation · Regimen source: FDA Propafenone · 2
- • 150 mg every 8 h; after at least 3–4 days to 225 then 300 mg every 8 h. Not with structural heart disease. FDA Propafenone · 2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Heart failure; cardiogenic shock; sinoatrial, AV or intraventricular conduction disorders without a pacemaker; Brugada syndrome; marked bradycardia or hypotension; bronchospastic disorders; electrolyte imbalance. FDA Propafenone · 4
Warnings
- • Boxed warning: increased mortality (CAST); reserve for documented life-threatening or symptomatic arrhythmias without structural heart disease. FDA Propafenone · Boxed Warning
Formulations
- 150 mg tablet (scored) — tablet 🇺🇸 USA FDA Propafenone · 3
- 225 mg tablet (scored) — tablet 🇺🇸 USA FDA Propafenone · 3
- 300 mg tablet (scored) — tablet 🇺🇸 USA FDA Propafenone · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Propafenone · 8.1
“Risk Summary There are no studies of propafenone hydrochloride in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Propafenone · 8.2
“Risk Summary Propafenone and its active metabolite, 5-OH-propafenone, are present in human milk, but the levels are likely to be low.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Propafenone · 8.4
“The safety and effectiveness of propafenone in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Propafenone · 8.5
“In general, dose selection for an elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Propafenone · 8.3
“Infertility Males: Based on human and animal studies, propafenone hydrochloride may transiently impair spermatogenesis in males.”
🔗 Reference links
- FDA (approval record)ANDA075938
- DailyMed (FDA label)FDA Propafenone
- MedlinePlus (NIH)Propafenone
- WHO ATC/DDDC01BC03
- Darooyab (Iran)Propafenone
🇮🇷 Registered in Iran Darooyab · G-1856/Propafenone
Dosage forms with Iranian generic codes, per Darooyab.
- 01065 · PROPAFENONE HCL 150MG CAP · کپسول پروپافنون هیدروکلراید ۱۵۰ میلیگرم
- 01777 · PROPAFENONE HCL 150MG TAB · قرص پروپافنون هیدروکلراید ۱۵۰ میلیگرم
- 01064 · PROPAFENONE HCL 300MG CAP · کپسول پروپافنون هیدروکلراید ۳۰۰ میلیگرم
- 01778 · PROPAFENONE HCL 300MG TAB · قرص پروپافنون هیدروکلراید ۳۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Propafenone · 3FDA Propafenone · 2FDA Propafenone · 4FDA Propafenone · Boxed WarningFDA Propafenone · 8.1FDA Propafenone · 8.2FDA Propafenone · 8.4FDA Propafenone · 8.5FDA Propafenone · 8.3FDA Propafenone · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1856/Propafenone
- Clinical review⚠ Unverified